Dexcom Verily G1 Approved, But Will It Launch?
Dexcom’s Verily Gen 1 CGM has received 510(k) clearance ahead of initial projections. Dexcom has not yet issued a press release announcing the approval, but will likely discuss it during the upcoming Q3 ’18 earnings call on November 6. Below, FENIX provides thoughts on the Verily G1 CGM including whether or not Dexcom will even launch the product. Pictured below is a slide from Irl Hirsch’s 2017 talk at AACE comparing Verily G1 (top) and Verily G2 (bottom). The continued CGM innovation back-and-forth between Dexcom and Abbott is very impressive and exciting for patients. Recall, Abbott’s 14-day Libre product and……
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.